Suvratoxumab (MEDI4893) is a long-acting, high-affinity humanized monoclonal antibody against α-toxin, which can effectively neutralize the key virulence factor of Staphylococcus aureus (α-toxin), also can improve the survival rate and reduce lung injury in a mouse model of pneumonia with immunocompromise, and at the same time can enhance the antibacterial activity of Vancomycin or Linezolid.

In the immunocompromised mouse pneumonia model, Suvratoxumab (5, 15, 45 mg/kg, single-strain administration) improved the survival rate of the model [1].
Suvratoxumab (15 mg/kg, single dose, single-strain administration) reduced lung injury in mice and enhanced macrophage phagocytosis [1].
Suvratoxumab (15 mg/kg, single dose) synergistically enhanced the therapeutic effect of antibiotics such as vancomycin and linezolid in mice [1].

Human

Monoclonal

Unconjugated